Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221711 | 0.77 | TP53 (0.54) | TP53MAPT | |
| SCHEMBL378949 | 0.75 | SMN1; SMN2 (0.62) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1920755 | 0.73 | NPC1 (0.60) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5309531 | 0.73 | TP53 (0.63) | TP53MAPT | |
| SCHEMBL17057465 | 0.72 | TP53 (1.00) | TP53MAPT | |
| SCHEMBL3971654 | 0.72 | TP53 (0.57) | TP53MAPT | |
| SCHEMBL21221811 | 0.71 | TP53 (0.61) | TP53MAPT | |
| SCHEMBL5298937 | 0.71 | TP53 (0.71) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL4082607 | 0.71 | MAPT (0.68) | TP53MAPT | |
| SCHEMBL6783250 | 0.71 | TP53 (0.73) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | ABCC1, MCL1, ABCC3 | TP53 8/4885MAPT 4452/4885RAB9A 1907/4885 |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | ABCC1, MCL1, ABCC3 | TP53 8/4885MAPT 4452/4885RAB9A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.